AV-380:n annoksen eskalaatiotutkimus metastasoituneilla syöpäpotilailla, joilla on kakeksia
Vaiheen 1 annoksen eskalaatiotutkimus AV-380:sta yhdistettynä tavalliseen hoitokemoterapiaan metastaattisilla syöpäpotilailla, joilla on kakeksia ja kohonneet GDF-15-tasot
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia. AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Tutkimuksen yleiskatsaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
California
-
Beverly Hills, California, Yhdysvallat, 90211
- Beverly Hills Cancer Center
-
Lakewood, California, Yhdysvallat, 90712
- Cancer and Blood Specialty Clinic
-
Newport Beach, California, Yhdysvallat, 92663
- Hoag Memorial Hospital
-
-
Connecticut
-
Hartford, Connecticut, Yhdysvallat, 06102
- Hartford Hospital
-
-
Florida
-
Orlando, Florida, Yhdysvallat, 32804
- Advent Health Orlando Hospital
-
-
Nebraska
-
Omaha, Nebraska, Yhdysvallat, 68130
- Nebraska Cancer Specialists
-
-
New Jersey
-
East Brunswick, New Jersey, Yhdysvallat, 08816
- Astera Cancer Care
-
-
New York
-
Shirley, New York, Yhdysvallat, 11967
- New York Cancer And Blood Specialists
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Yhdysvallat, 29425
- MUSC Hollings Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37232
- Vanderbilt University Henry-Joyce Cancer Clinic
-
-
Texas
-
Kingwood, Texas, Yhdysvallat, 77339
- Community Clinical Trials
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Patient must be ≥ 18 years of age at the time of signing the informed consent.
-
Patients with histologically confirmed solid tumor cancer who are actively receiving SoC therapy for this cancer.
-
Patients with cachexia as defined by Fearon criteria:
- Weight loss > 5% over past 6 months (in absence of simple starvation), or
- BMI < 20 kg/m2 and any degree of weight loss > 2%, or
- Sarcopenia and any degree of weight loss > 2%
-
Patients with life expectancy ≥ 3 months
Exclusion Criteria:
- History of allergic or anaphylactic reaction to any monoclonal antibody (IgG protein) or molecules made of components of monoclonal antibody
- Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 2 weeks before first dose of study treatment.
- Myocardial infarction or heart failure of New York Heart Association Grade 3-4 within 3 months prior to start of protocol therapy
- Uncontrolled pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Cachexia is caused by other reasons (e.g., severe chronic obstructive pulmonary disease, heart failure, or HIV/AIDS), or the patient has uncontrolled reversible causes of reduced oral food intake, including, but not limited to, oral mucositis, nausea/vomiting, diarrhea, and/or obstruction, impairing the patient's ability to eat as determined by the Investigator.
- Patients receiving tube feedings or parenteral nutrition at the time of Screening.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Dose Escalation Cohorts
Experimental: Dose escalation cohorts of AV-380 administered by IV infusion |
AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Assessment of adverse events (AEs)
Aikaikkuna: From enrollment to the last follow-up visit approximately 60-days post dose
|
AEs as characterized by incidence, type, frequency, and severity (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE]) |
From enrollment to the last follow-up visit approximately 60-days post dose
|
|
Toxicity
Aikaikkuna: While receiving study drug (up to 4 months)
|
Dose-limiting Toxicity (DLT) events observed at increasing doses of AV-380 |
While receiving study drug (up to 4 months)
|
|
Laboratory Abnormalities
Aikaikkuna: From enrollment to the last follow-up visit approximately 60-days post dose.
|
Laboratory abnormalities as characterized by type, frequency, severity (graded according to NCI-CTCAE v5.0) and timing. |
From enrollment to the last follow-up visit approximately 60-days post dose.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Cmax
Aikaikkuna: From first dose to the last follow-up visit approximately 60-days post dose.
|
Maximum observed plasma concentration for AV-380 |
From first dose to the last follow-up visit approximately 60-days post dose.
|
|
Tmax
Aikaikkuna: From first dose to the last follow-up visit approximately 60-days post dose
|
Time to reach the Cmax for AV-380 |
From first dose to the last follow-up visit approximately 60-days post dose
|
|
AUC(0-t)
Aikaikkuna: From first dose to the last follow-up visit approximately 60-days post dose.
|
Area under the plasma concentration-time curve from zero time to the last measurable point for AV-380 |
From first dose to the last follow-up visit approximately 60-days post dose.
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
GDF-15: n seerumin taso
Aikaikkuna: Ilmoittautumisesta viimeiseen seurantakäyntiin noin 60 päivän jälkeiseen annokseen.
|
Ilmoittautumisesta viimeiseen seurantakäyntiin noin 60 päivän jälkeiseen annokseen.
|
|
|
Immunogenicity
Aikaikkuna: From first dose to the last follow-up visit approximately 60-days post dose.
|
Serum levels of Anti-Drug Antibody (ADA) against AV-380 and their potential relationship with AEs and serum levels of GDF-15 |
From first dose to the last follow-up visit approximately 60-days post dose.
|
|
Weight
Aikaikkuna: From enrollment to the last follow-up visit approximately 60-days post dose.
|
Change from baseline body weight during the study |
From enrollment to the last follow-up visit approximately 60-days post dose.
|
|
Patient-Reported Outcomes
Aikaikkuna: From enrollment to the end of treatment, approximately 4 months
|
Change from baseline in the following questionnaires: Functional Assessment of Anorexia Cachexia Therapy (FAACT); Patient global impression of severity (PGI-S) and patient global impression of change (PGI-C) for appetite, fatigue, and physical activity. |
From enrollment to the end of treatment, approximately 4 months
|
|
Lumbar (L3) Skeletal Muscle Index (L3SMI)
Aikaikkuna: From enrollment to the end of treatment, approximately 4 months
|
Measurement of a cross-sectional area of muscle at the level of the third lumbar vertebra (L3) using computed tomography (CT) scan |
From enrollment to the end of treatment, approximately 4 months
|
|
Physical Function
Aikaikkuna: From enrollment to the end of treatment, approximately 4 months
|
Change from baseline in physical function endpoints, including Short Physical Performance Battery test and digital measures of non-sedentary time |
From enrollment to the end of treatment, approximately 4 months
|
|
Albumin and CRP
Aikaikkuna: From enrollment to the last follow-up visit approximately 60-days post dose.
|
Change from baseline in albumin and CRP levels |
From enrollment to the last follow-up visit approximately 60-days post dose.
|
|
Tumor status
Aikaikkuna: From enrollment to the last follow-up visit approximately 60-days post dose.
|
Evaluate the effect of AV-380 on tumor burden and tumor status, per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) |
From enrollment to the last follow-up visit approximately 60-days post dose.
|
|
Biomarkers
Aikaikkuna: From first dose to the last follow-up visit approximately 60-days post dose.
|
including activin A and cytokine levels (e.g., monocyte chemoattractant protein-1 [MCP-1] and proinflammatory) |
From first dose to the last follow-up visit approximately 60-days post dose.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- AV-380-22-102
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .